Literature DB >> 27319577

Tumour heterogeneity in glioblastoma assessed by MRI texture analysis: a potential marker of survival.

David Molina1, Julián Pérez-Beteta1, Belén Luque1, Elena Arregui2, Manuel Calvo2, José M Borrás2, Carlos López2, Juan Martino3, Carlos Velasquez3, Beatriz Asenjo4, Manuel Benavides4, Ismael Herruzo4, Alicia Martínez-González1, Luis Pérez-Romasanta5, Estanislao Arana6, Víctor M Pérez-García1.   

Abstract

OBJECTIVE: : The main objective of this retrospective work was the study of three-dimensional (3D) heterogeneity measures of post-contrast pre-operative MR images acquired with T1 weighted sequences of patients with glioblastoma (GBM) as predictors of clinical outcome.
METHODS: : 79 patients from 3 hospitals were included in the study. 16 3D textural heterogeneity measures were computed including run-length matrix (RLM) features (regional heterogeneity) and co-occurrence matrix (CM) features (local heterogeneity). The significance of the results was studied using Kaplan-Meier curves and Cox proportional hazards analysis. Correlation between the variables of the study was assessed using the Spearman's correlation coefficient.
RESULTS: : Kaplan-Meyer survival analysis showed that 4 of the 11 RLM features and 4 of the 5 CM features considered were robust predictors of survival. The median survival differences in the most significant cases were of over 6 months.
CONCLUSION: : Heterogeneity measures computed on the post-contrast pre-operative T1 weighted MR images of patients with GBM are predictors of survival. ADVANCES IN KNOWLEDGE:: Texture analysis to assess tumour heterogeneity has been widely studied. However, most works develop a two-dimensional analysis, focusing only on one MRI slice to state tumour heterogeneity. The study of fully 3D heterogeneity textural features as predictors of clinical outcome is more robust and is not dependent on the selected slice of the tumour.

Entities:  

Year:  2016        PMID: 27319577      PMCID: PMC5124892          DOI: 10.1259/bjr.20160242

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  25 in total

1.  The influence of field strength and different clinical breast MRI protocols on the outcome of texture analysis using foam phantoms.

Authors:  Shelley A Waugh; Richard A Lerski; Luc Bidaut; Alastair M Thompson
Journal:  Med Phys       Date:  2011-09       Impact factor: 4.071

2.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

Authors:  Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang
Journal:  J Clin Oncol       Date:  2010-03-15       Impact factor: 44.544

Review 3.  Texture analysis of medical images.

Authors:  G Castellano; L Bonilha; L M Li; F Cendes
Journal:  Clin Radiol       Date:  2004-12       Impact factor: 2.350

Review 4.  Imaging Genomics in Gliomas.

Authors:  Pascal O Zinn; Zeeshan Mahmood; Mohamed G Elbanan; Rivka R Colen
Journal:  Cancer J       Date:  2015 May-Jun       Impact factor: 3.360

Review 5.  Heterogeneity maintenance in glioblastoma: a social network.

Authors:  Rudy Bonavia; Maria-del-Mar Inda; Webster K Cavenee; Frank B Furnari
Journal:  Cancer Res       Date:  2011-05-31       Impact factor: 12.701

Review 6.  Radiogenomics and imaging phenotypes in glioblastoma: novel observations and correlation with molecular characteristics.

Authors:  Benjamin M Ellingson
Journal:  Curr Neurol Neurosci Rep       Date:  2015-01       Impact factor: 5.081

7.  Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer.

Authors:  Florent Tixier; Catherine Cheze Le Rest; Mathieu Hatt; Nidal Albarghach; Olivier Pradier; Jean-Philippe Metges; Laurent Corcos; Dimitris Visvikis
Journal:  J Nucl Med       Date:  2011-02-14       Impact factor: 10.057

8.  Evaluation of tumor-derived MRI-texture features for discrimination of molecular subtypes and prediction of 12-month survival status in glioblastoma.

Authors:  Dalu Yang; Ganesh Rao; Juan Martinez; Ashok Veeraraghavan; Arvind Rao
Journal:  Med Phys       Date:  2015-11       Impact factor: 4.071

9.  Hepatic entropy and uniformity: additional parameters that can potentially increase the effectiveness of contrast enhancement during abdominal CT.

Authors:  B Ganeshan; K A Miles; R C D Young; C R Chatwin
Journal:  Clin Radiol       Date:  2007-05-23       Impact factor: 2.350

Review 10.  Improving tumour heterogeneity MRI assessment with histograms.

Authors:  N Just
Journal:  Br J Cancer       Date:  2014-09-30       Impact factor: 7.640

View more
  17 in total

1.  Imaging prediction of nonalcoholic steatohepatitis using computed tomography texture analysis.

Authors:  Shotaro Naganawa; Kenichiro Enooku; Ryosuke Tateishi; Hiroyuki Akai; Koichiro Yasaka; Junji Shibahara; Tetsuo Ushiku; Osamu Abe; Kuni Ohtomo; Shigeru Kiryu
Journal:  Eur Radiol       Date:  2018-02-05       Impact factor: 5.315

2.  A mesoscopic simulator to uncover heterogeneity and evolutionary dynamics in tumors.

Authors:  Juan Jiménez-Sánchez; Álvaro Martínez-Rubio; Anton Popov; Julián Pérez-Beteta; Youness Azimzade; David Molina-García; Juan Belmonte-Beitia; Gabriel F Calvo; Víctor M Pérez-García
Journal:  PLoS Comput Biol       Date:  2021-02-10       Impact factor: 4.475

3.  Relationship between Glioblastoma Heterogeneity and Survival Time: An MR Imaging Texture Analysis.

Authors:  Y Liu; X Xu; L Yin; X Zhang; L Li; H Lu
Journal:  AJNR Am J Neuroradiol       Date:  2017-06-29       Impact factor: 3.825

4.  Clinical-Radiomics Nomogram from T1W, T1CE, and T2FS MRI for Improving Diagnosis of Soft-Tissue Sarcoma.

Authors:  Zhibin Yue; Xiaoyu Wang; Yan Wang; Hongbo Wang; Wenyan Jiang
Journal:  Mol Imaging Biol       Date:  2022-07-07       Impact factor: 3.484

5.  Differentiation of progressive disease from pseudoprogression using MRI histogram analysis in patients with treated glioblastoma.

Authors:  Mustafa Yildirim; Murat Baykara
Journal:  Acta Neurol Belg       Date:  2021-02-08       Impact factor: 2.396

6.  Heterogeneous parameters based on 18F-FET PET imaging can non-invasively predict tumor grade and isocitrate dehydrogenase gene 1 mutation in untreated gliomas.

Authors:  Tao Hua; Weiyan Zhou; Zhirui Zhou; Yihui Guan; Ming Li
Journal:  Quant Imaging Med Surg       Date:  2021-01

7.  Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients.

Authors:  David Molina; Julián Pérez-Beteta; Alicia Martínez-González; Juan M Sepúlveda; Sergi Peralta; Miguel J Gil-Gil; Gaspar Reynes; Ana Herrero; Ramón De Las Peñas; Raquel Luque; Jaume Capellades; Carmen Balaña; Víctor M Pérez-García
Journal:  PLoS One       Date:  2016-08-24       Impact factor: 3.240

8.  Textural features and SUV-based variables assessed by dual time point 18F-FDG PET/CT in locally advanced breast cancer.

Authors:  Ana María Garcia-Vicente; David Molina; Julián Pérez-Beteta; Mariano Amo-Salas; Alicia Martínez-González; Gloria Bueno; María Jesús Tello-Galán; Ángel Soriano-Castrejón
Journal:  Ann Nucl Med       Date:  2017-09-08       Impact factor: 2.668

9.  Non-standard radiotherapy fractionations delay the time to malignant transformation of low-grade gliomas.

Authors:  Araceli Henares-Molina; Sebastien Benzekry; Pedro C Lara; Marcial García-Rojo; Víctor M Pérez-García; Alicia Martínez-González
Journal:  PLoS One       Date:  2017-06-01       Impact factor: 3.240

10.  The Effect of Heterogenous Subregions in Glioblastomas on Survival Stratification: A Radiomics Analysis Using the Multimodality MRI.

Authors:  Lulu Yin; Yan Liu; Xi Zhang; Hongbing Lu; Yang Liu
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.